MA55799A - COMBINATION THERAPIES INCLUDING APRMILAST AND TYK2 INHIBITORS - Google Patents

COMBINATION THERAPIES INCLUDING APRMILAST AND TYK2 INHIBITORS

Info

Publication number
MA55799A
MA55799A MA055799A MA55799A MA55799A MA 55799 A MA55799 A MA 55799A MA 055799 A MA055799 A MA 055799A MA 55799 A MA55799 A MA 55799A MA 55799 A MA55799 A MA 55799A
Authority
MA
Morocco
Prior art keywords
aprmilast
combination therapies
therapies including
tyk2 inhibitors
tyk2
Prior art date
Application number
MA055799A
Other languages
French (fr)
Inventor
Mary Adams
Lisa Beebe
Gilles Buchwalter
Tiffany Carr
Robert Plenge
Peter Henry Schafer
Te-Chen Tzeng
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MA55799A publication Critical patent/MA55799A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MA055799A 2019-04-30 2020-04-30 COMBINATION THERAPIES INCLUDING APRMILAST AND TYK2 INHIBITORS MA55799A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/029772 WO2020222773A1 (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors

Publications (1)

Publication Number Publication Date
MA55799A true MA55799A (en) 2022-03-09

Family

ID=66476870

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055799A MA55799A (en) 2019-04-30 2020-04-30 COMBINATION THERAPIES INCLUDING APRMILAST AND TYK2 INHIBITORS

Country Status (14)

Country Link
EP (2) EP3962475A1 (en)
JP (2) JP2022537877A (en)
KR (2) KR20220002488A (en)
CN (3) CN114269336A (en)
AU (2) AU2019443366A1 (en)
BR (2) BR112021021809A2 (en)
CA (2) CA3138473A1 (en)
CL (1) CL2021002847A1 (en)
CO (2) CO2021015614A2 (en)
IL (2) IL287665A (en)
MA (1) MA55799A (en)
MX (2) MX2021013317A (en)
SG (2) SG11202112043PA (en)
WO (2) WO2020222773A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202112043PA (en) * 2019-04-30 2021-11-29 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors
CA3208361A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
EP4294806A1 (en) 2021-02-19 2023-12-27 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
AU2022222470A1 (en) 2021-02-19 2023-09-21 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
JP7740849B2 (en) * 2021-05-04 2025-09-17 シャンハイ ゼイ バイオテクノロジー カンパニー リミテッド Nitrogen-containing heterocyclic pyridine compounds
EP4404930A1 (en) * 2021-09-23 2024-07-31 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US8367689B2 (en) * 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
JP2014500254A (en) 2010-11-09 2014-01-09 セルゾーム リミティッド Pyridine compounds and their aza analogs as TYK2 inhibitors
JP6022548B2 (en) * 2011-04-28 2016-11-09 セルジーン コーポレイション Methods and compositions for using PDE4 inhibitors in the treatment and management of autoimmune and inflammatory diseases
RS60415B1 (en) * 2011-12-27 2020-07-31 Amgen (Europe) GmbH Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
CN104159891B (en) 2012-01-10 2016-09-07 霍夫曼-拉罗奇有限公司 Pyridazine amide compound and they are as the purposes of SYK inhibitor
WO2013146963A1 (en) 2012-03-28 2013-10-03 武田薬品工業株式会社 Heterocyclic compound
BR112014029310A2 (en) 2012-05-24 2018-06-26 Cellzome Ltd heterocyclic pyrimidine analogs as tyk2 inhibitors
ES2648226T3 (en) 2012-11-08 2017-12-29 Bristol-Myers Squibb Company Alkylamide substituted pyrimidine compounds useful in the modulation of IL-12, IL-23 and / or IFN
LT3495358T (en) 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
WO2014151180A1 (en) * 2013-03-14 2014-09-25 Celgene Corporation Treatment of psoriatic arthritis using apremilast
JPWO2015016206A1 (en) 2013-07-30 2017-03-02 武田薬品工業株式会社 Heterocyclic compounds
MX369974B (en) 2013-09-03 2019-11-27 Sareum Ltd Pharmaceutical compounds.
TWI582077B (en) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 Alkyl-nonylamine substituted pyridine compound as a regulator of IL-12, IL-23 and/or IFNα response
ES2702126T3 (en) 2013-12-10 2019-02-27 Bristol Myers Squibb Co Imidazopyridazine compounds useful as modulators of responses to IL-12, IL-23 and / or IFN alpha
WO2015091584A1 (en) 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors
US9834548B2 (en) * 2014-02-14 2017-12-05 Portola Pharmaceuticals, Inc. Pyridazine compounds as JAK inhibitors
WO2015131080A1 (en) 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
MX2016014384A (en) * 2014-06-23 2017-01-20 Celgene Corp Apremilast for the treatment of a liver disease or a liver function abnormality.
US10092541B2 (en) * 2014-08-15 2018-10-09 Celgene Corporation Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
NO2721710T3 (en) 2014-08-21 2018-03-31
WO2016047678A1 (en) 2014-09-25 2016-03-31 武田薬品工業株式会社 Heterocyclic compound
TWI788655B (en) 2015-02-27 2023-01-01 美商林伯士拉克許米公司 Tyk2 inhibitors and uses thereof
TWI707852B (en) 2015-09-02 2020-10-21 美商林伯士拉克許米公司 Tyk2 inhibitors and uses thereof
CN109071546B (en) 2016-02-24 2021-03-02 辉瑞大药厂 Pyrazolo [1,5-A ] pyrazin-4-yl derivatives as JAK inhibitors
ES2902995T3 (en) 2016-10-07 2022-03-30 Bristol Myers Squibb Co Imidazopyridazine compounds useful as modulators of responses to IL-12, IL-23 and/or IFN alpha
US10323036B2 (en) 2016-10-14 2019-06-18 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
KR102477063B1 (en) 2016-10-28 2022-12-12 브리스톨-마이어스 스큅 컴퍼니 Heterobicyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
EP3541817B1 (en) 2016-11-17 2020-12-23 Bristol-Myers Squibb Company Imidazopyridazine modulators of il-12, il-23 and/or ifn-alpha
GB2562702B (en) 2017-03-06 2022-05-18 Linear Shaped Ltd Frame and linear shaped charge
TW202515876A (en) * 2017-03-08 2025-04-16 日商武田藥品工業股份有限公司 Tyk2 inhibitors and uses thereof
SG11202112043PA (en) * 2019-04-30 2021-11-29 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors

Also Published As

Publication number Publication date
BR112021021826A8 (en) 2022-06-21
KR20220002489A (en) 2022-01-06
SG11202112043PA (en) 2021-11-29
CN114269336A (en) 2022-04-01
CA3138686A1 (en) 2020-11-05
CN119454692A (en) 2025-02-18
JP2022537877A (en) 2022-08-31
WO2020223431A1 (en) 2020-11-05
MX2021013318A (en) 2022-01-31
SG11202112018YA (en) 2021-11-29
AU2019443366A1 (en) 2021-12-02
CO2021015614A2 (en) 2021-12-10
AU2020266143A1 (en) 2021-12-02
EP3962476A1 (en) 2022-03-09
IL287665A (en) 2022-07-01
CN114206333A (en) 2022-03-18
CL2021002847A1 (en) 2022-07-22
EP3962475A1 (en) 2022-03-09
JP7453251B2 (en) 2024-03-19
MX2021013317A (en) 2022-01-18
BR112021021826A2 (en) 2022-01-04
IL287670A (en) 2021-12-01
WO2020222773A1 (en) 2020-11-05
CA3138473A1 (en) 2020-11-05
JP2022537878A (en) 2022-08-31
KR20220002488A (en) 2022-01-06
BR112021021809A2 (en) 2022-01-04
CO2021015622A2 (en) 2022-02-28

Similar Documents

Publication Publication Date Title
MA55799A (en) COMBINATION THERAPIES INCLUDING APRMILAST AND TYK2 INHIBITORS
IL282487A (en) TYK2 inhibitors and their use
IL286248A (en) tyk2 inhibitors and their use
GB201909190D0 (en) Therapeutic agents
MA44890A (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
GB201909191D0 (en) Therapeutic agents
GB201909194D0 (en) Therapeutic agents
EP3906029A4 (en) MENIN-MLL INTERACTION INHIBITORS
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
MA46716A (en) CELL THERAPY AND MICROGLIA INHIBITOR POLYTHERAPY
IL284799A (en) TYK2 inhibitors and uses thereof
MA52165A (en) SELECTIVE TGFBETA1 ISOFORM INHIBITORS AND ASSOCIATED USE
EP3773605A4 (en) MODIFIED HINGE-REGION 1 AND / OR 4 DYSTROPHINS FOR DYSTROPHINOPATHY THERAPY
IL279810A (en) Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
EP3609864C0 (en) HDAC6 INHIBITORS AND IMAGING AGENTS
EP4103186A4 (en) MONOTHERAPIES AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS
GB201902277D0 (en) Therapeutic agents
MA47074A (en) DOSAGE FORMS CONSISTING OF TASK-1 AND TASK-3 CHANNEL INHIBITORS AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISORDERS
IL287704A (en) Use of cannabidiol in the treatment of multiple sclerosis complex
GB201905520D0 (en) Compounds and their therapeutic use
EP3820382C0 (en) SYSTEMS INCLUDING ALIGNMENT GUIDES AND IMPLANTS
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
GB201918541D0 (en) Therapeutic compounds and their use
IL279178A (en) Modified cas9 protein and use thereof
GB201906804D0 (en) Therapeutic agents